Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine + oxaliplatin in gall bladder or biliary tract cancer
ISRCTN40839737Phase 2Completed
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Jul 2003
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and oxaliplatin in gallbladder cancer and biliary cancer, sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Objective response rate. Started Jul 2003; status: completed.
02
Drugs
capecitabineoxaliplatin
03
Conditions
gallbladder cancerbiliary cancer
Beyond the preview
Go deeper on ISRCTN40839737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN40839737.